In 2010, Stemgent was the first company to commercialize mRNA reprogramming. Today, our broad range of products and services for stem cell scientists are used by leading pharmaceutical and biotechnology companies as well as top academic and government research institutions all around the globe.
REPROCELL Brand:Stemgent
Well known in the global stem cell research community, the Stemgent™ brand stands for performance-qualified reagents and innovation.

Anti-TRA-1-60 staining of iPSCs.

Anti-nanog staining of fibroblast derived iPSCs.

Tyrosine Hydroxylase/βIII-Tubulin staining of iPSC-derived dopaminergic neurons

iPSCs generated from urine-derived cells, βIII-Tubulin/Nesting staining

Clinical iPSC Production Service
REPROCELL can provide you with clinical iPSCs for your therapeutic project, created with our state-of-the-art RNA reprogramming technology. You can test our clonal lines for suitability before scaling up to a GMP Master Cell Bank.
Research Stem Cell Services
Footprint-free iPSC reprogramming and differentiation.
REPROCELL Stemgent’s 3rd Generation RNA Reprogramming Technology
Our latest reprogramming technology, StemRNA™ 3rd Gen, provides the highest efficiency footprint-free reprogramming available to generate high-quality ready-to-use iPSCs.
Besides being available in kit form for stem cell scientists (the StemRNA™ 3rd Gen Reprogramming Kit, product #00-0076), this same proprietary reprogramming technology forms the basis of REPROCELL's global iPSC reprogramming service.
When combined with comprehensive REPROCELL know-how from our stem cell labs on four continents, StemRNA 3rd Gen RNA reprogramming technology provides our clients with a full range of iPSC services including:
Our customers include pharmaceutical and biotechnology companies, as well as top academic and government research institutions from around the globe.
StemRNA 3rd Gen RNA reprogramming technology and iPSC usage can also be made available for various commercial applications with licenses available through REPROCELL Inc.
Stemgent Product Sub-Brands
mRNA Reprogramming Technology
StemRNA is a brand of Stemgent for our mRNA-based reprogramming technology and kits, and the cells derived from iPS cells generated using this technology. StemRNA reprogramming technology offers vector-free, rapid, high-efficiency reprogramming of fibroblasts and blood and urine cells to generate clinically relevant iPS cells ready for differentiation.
Small Molecules
Stemolecule is a brand of Stemgent for a series of small molecules that are reagents useful for stem cell reprogramming, maintenance or differentiation. Most Stemolecules such as Y27632 and CHIR99021 are enzyme inhibitors. Stemolecules are high quality reagents sourced from suppliers that have been validated by REPROCELL for products that have superior performance in stem cell applications.
Antibodies for Cell-Specific Pluripotency Markers
StemAB is a brand of Stemgent for our portfolio of antibodies targeted against stem cell-specific pluripotency markers. StemAB antibodies are validated for use a variety of applications including FACS and immunofluorescence microscopy staining. StemAB antibodies are useful for monitoring the quality of iPS cells and ES Cells after reprogramming or isolation.
Growth Factors & Cytokines
Stemfactor is a brand of Stemgent for a series of growth factors, cytokines and other purified proteins that are reagents useful for stem cell reprogramming, maintenance or differentiation. Stemfactors are high quality reagents sourced from suppliers that have been validated by REPROCELL for products that have superior performance in stem cell applications.
The history of Stemgent
The Stemgent brand of REPROCELL has it origins in 2008 when the company was founded with offices in Cambridge, MA and San Diego, CA. The corporate business model was to commercialize research tools for induced pluripotent stem cell (iPSC) research, including reprogramming technologies and stem cell reagents. In 2014, Stemgent was acquired by REPROCELL, and in 2017, Stemgent moved to Beltsville, MD.
Stemgent’s reputation was built on cutting-edge mRNA-based iPSC reprogramming technology and a portfolio of stem cell–qualified reagents including small molecules (Stemolecule™) and protein factors (StemFactor™) to facilitate reprogramming and stem cell growth and maintenance.
Timeline
2016 – Stemgent merges operations with Bioserve (Beltsville, MD) to become part of REPROCELL USA Inc.
2014 – Stemgent iPS cell business unit is acquired by REPROCELL company (Japan).
2010 – Stemgent held the first commercially available iPS training course at the National Institute of Health facility.
2010 – Stemgent and Miltenyi Biotec announced partnership for co-development and worldwide sale of stem cell research products.
2009 – Stemgent is voted as one of the Top 25 up-and-coming biotechnology companies by a prominent global publishing organization.
2008 – Stemgent is founded, offering the first set of research tools focused on cellular reprogramming.
Speak to our experts
REPROCELL Brand: Stemgent
Gene Editing Services
Stemgent Products
On the REPROCELL blog
Latest in Stem Cells

Breaking Barriers in Women’s Health: The World’s First Live Birth Using Fertilo
Discover how Gameto achieved the world’s first live birth using Fertilo, a revolutionary in vitro oocyte maturation technology. Learn about its stem cell-driven innovation and how it's transforming fertility care for women worldwide.
21 January 2025

Discover the differentiation potential of induced pluripotent stem cells (iPSC) to cytotoxic NK cells, including recent advancements in research and therapy.
16 October 2024

What you should know about the FDA’s Biological License Application Process
Learn about the FDA's Biological License Application process, including submission requirements, review phases, and expedited pathways for biologics approvals.
19 September 2024

REPROCELL USA Inaugurates New GMP Laboratory
May 15, 2024: REPROCELL USA inaugurated its new GMP BioManufacturing Lab. The facility enables hiPSC and hMSC generation in a contaminant-free environment.
07 June 2024

Harnessing the Power of Mesenchymal Stem Cells
Discover the groundbreaking potential of Mesenchymal Stem Cells (MSCs) in biomedical research and therapeutic development.
27 May 2024